Epigenetic Modifications: Therapeutic Potential in Cancer
AUTOR(ES)
Sachan, Manisha, Kaur, Manpreet
FONTE
Braz. arch. biol. technol.
DATA DE PUBLICAÇÃO
2015-08
RESUMO
Epigenetic modifications and alterations in chromatin structure and function contribute to the cumulative changes observed as normal cells undergo malignant transformation. These modifications and enzymes (DNA methyltransferases, histone deacetylases, histone methyltransferases, and demethylases) related to them have been deeply studied to develop new drugs, epigenome-targeted therapies and new diagnostic tools. Epigenetic modifiers aim to restore normal epigenetic modification patterns through the inhibition of epigenetic modifier enzymes. Four of them (azacitidine, decitabine, vorinostat and romidepsin) are approved by the U.S. Food and Drug Administration. This article provides an overview about the known functional roles of epigenetic enzymes in cancer development.
Documentos Relacionados
- Histone modifications: Now summoning sumoylation
- Histone modifications: Combinatorial complexity or cumulative simplicity?
- The RESID Database of Protein Modifications: 2003 developments
- The RESID Database of protein structure modifications: 2000 update
- Emerging titanium surface modifications: The war against polymicrobial infections on dental implants